| Literature DB >> 25649849 |
Yao Zou1, Xiaoming Zhu, Hassan Mushtaq Muhammad, Ping Jiang, Yufeng Li.
Abstract
Recently, a series of acute swine erysipelas outbreaks occurred in Eastern China. Eight strains isolated from cases of septicemia were determined as serotype 1a, and 4 of the isolates were resistant to acriflavine. One isolate strain named HX130709 was attenuated on agar media containing acriflavine dye. The 432-bp hypervariable region in spaA gene of the field and attenuated strains were amplified and sequenced. It was further compared with the vaccine strain G4T10, and thus, the eight field strains can be divided into four spaA-types. The partial spaA gene analysis also showed that no point mutations occurred among different archived passages of HX130709 during the attenuation. Results of pulsed-field gel electrophoresis showed that eight distinct patterns with 22 to 30 DNA fragment bands were produced from field strains, and twelve distinct patterns with 23 to 27 DNA fragment bands were produced from different passages of the attenuated strains. Mouse pathogenicity test showed that the mortality of the mice infected with 10(4) CFU field strains was 100% and the attenuation of strain HX130709 occurred between 46 and 50 passages. All the field and attenuated strains were highly sensitive to β-lactam antibiotics, tetracyclines and macrolides. So, we can make conclusions that the acute swine erysipelas outbreaks in Eastern China were caused by serotype 1a E. rhusiopathiae strains with different biochemical characteristics, and the virulence of serotype 1a E. rhusiopathiae strains is unrelated with some point mutations in 432-bp hypervariable region of the spaA gene.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25649849 PMCID: PMC4488401 DOI: 10.1292/jvms.14-0589
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Strains used in the study and eight field strains isolated from cases of septicemia causing acute death of fattening pigs and postpartum sows in Eastern China
| Strains | Date Isolated | Area Isolated | GenBank | Serotype | Country of |
|---|---|---|---|---|---|
| Serotype 1a (Fujisawa) | unknown | unknown | AB259652.1 | 1a | Japan |
| G4T10 | unknown | unknown | KJ645072 | 1a | unknown |
| SY091027 | 27/10/2009 | Siyang | KJ645080 | 1a | China |
| NZ130701 | 01/07/2013 | Nanzhang | KJ645073 | 1a | China |
| HX130709 | 09/07/2013 | Hexian | KJ645074 | 1a | China |
| XC130710 | 10/07/2013 | Xuancheng | KJ645075 | 1a | China |
| SH130723 | 23/07/2013 | Sihong | KJ645076 | 1a | China |
| YC130820a) | 20/08/2013 | Yancheng | KJ645077 | 1a | China |
| YC130828a) | 28/08/2013 | Yancheng | KJ645078 | 1a | China |
| YC131115a) | 15/11/2013 | Yancheng | KJ645079 | 1a | China |
a) Isolates YC130820, YC130828 and YC131115 were originated from three different farms in Yancheng.
Fig. 1.Genetic relationship between 8 E. rhusiopathiae field isolates and 1 vaccine strain and schematic representation of 8 different PFGE patterns obtained after restriction digestion with Sma I. The classification and divergence of isolates were calculated by the unweighted pair group method with averages from the PFGE results. At 5% divergence, 3 PFGE groups (A-C) were present; group A was subgrouped into A1/A2 at 3.5% divergence.
Acriflavine resistance of E. rhusiopathiae field isolates and vaccine reference strains
| Strain | MIC of Acriflavine | Acriflavine |
|---|---|---|
| SY091027 | 0.02 | R |
| NZ130701 | 0.005 | S |
| HX130709 | 0.0025 | S |
| XC130710 | 0.02 | R |
| SH130723 | 0.02 | R |
| YC130820 | 0.0025 | S |
| YC130828 | 0.005 | S |
| YC131115 | 0.0175 | R |
| G4T10 (vaccine) | 0.02 | R |
a) Resistant (R) or sensitive (S) to 0.01% acriflavine.
Substitutions in nucleotide and amino acid in a 432-bp hypervariable region on the spaA gene of 8 E. rhusiopathiae field strains compared with the corresponding sequence of the vaccine strain G4T10
| Substitution | Substitutions (position [nucleotide], amino acid a) ) | No. of nucleotide | |||||
|---|---|---|---|---|---|---|---|
| 584 (A) | 590 (T) | 609 (T) | 769 (A) | 885 (A) | |||
| D>A | I>T | I>M | I>L | NS | |||
| Pattern 1 | |||||||
| NZ130701 | C | 1 | a | ||||
| YC130820 | C | 1 | a | ||||
| SY091027 | C | 1 | a | ||||
| Pattern 2 | |||||||
| HX130709 | G | 1 | b | ||||
| SH130723 | G | 1 | b | ||||
| YC131115 | G | 1 | b | ||||
| Pattern 3 | |||||||
| YC130828 | C | G | 2 | c | |||
| Pattern4 | |||||||
| XC130710 | C | G | 2 | d | |||
| Reference strain | |||||||
| Fujisawab) | C | 1 | |||||
a) Original amino acid > substituted amino acid; NS=no amino acid mutation; G=glycine; D=aspartic acid; N=asparagine; A=alanine; I=isoleucine; T=threonine; M=methionine; L= leucine; E=glutamic acid. b) Japanese official challenge strain.
Nucleotide substitutions in a 432-bp hypervariable region on the spaA gene of 11 E. rhusiopathiae strains during the attenuation compared with the corresponding sequence of the original strain HX130709
| Concentration of | Number of | Bacteria collected | No. of nucleotide | spaA type |
|---|---|---|---|---|
| 0.0025 | F1-F4 | |||
| 0.00375 | F5-F7 | F5 | 0 | b |
| 0.005 | F8-F10 | F10 | 0 | b |
| 0.0125 | F11-F12 | |||
| 0.02 | F13-F27 | F15, F20, F25 | 0 | b |
| 0.0225 | F28-F38 | F30, F35 | 0 | b |
| 0.025 | F39-F45 | F40, F45 | 0 | b |
| 0.0275 | F46-F48 | |||
| 0.03 | F49-F55 | F50, F55 | 0 | b |
| Reference strain | ||||
| HX130709 | F0 | b |
Fig. 2.PFGE patterns produced from 8 erysipelas field isolates and 1 vaccine strain digested with Sma I. Lanes: 1, G4T10; 2, NZ130701; 3, HX130709; 4, XC130710; 5, SH130723; 6, YC130820; 7, YC130828; 8, SY091027; 9, YC131115; M, Lambda ladder PFG marker (N0340s, NEB).
Fig. 3.Genetic relationship among the 12 archived E. rhusiopathiae strains during the attenuation and their pathogenicity towards mice. The classification and divergence of the strains were calculated by the unweighted pair group method with averages from the PFGE results (Supplemental Fig. 1). At 5.8% divergence, 2 PFGE groups (A-B) were present. Most of the strains (9/12) were within group A in which these 9 strains shared over 99.5% identity with each other. Each mouse in different groups was injected with 0.1 ml PBS and 104 CFU strains F0-F55, respectively. Mice were observed daily to detect clinical signs of the disease for the subsequent 14 days. Only 3 groups survived for the end of the experiment after receiving subcutaneous injections of 104 CFU of strains F50 and F55 and PBS, while other groups injected with 104 CFU of strains F0-F45 died within 5 days.
Fig. 4.Pathogenicity of the 8 E. rhusiopathiae field strains towards mice. Each mouse of the untreated control group received a subcutaneous injection of 0.1 ml PBS in the right groin and was observed every 12 hr as others. Almost every mouse injected with 104 CFU E. rhusiopathiae field strains died within 72 hr, while all mice injected with 104 vaccine strain G4T10 and PBS survived for the end of the experiment.
Antimicrobial susceptibility testing results of 8 E. rhusiopathiae field strains, the vaccine strain G4T10 and the attenuated strain HX130709a
| Antibiotical | Diameter of bacteriostatic circle (mm) b) | No. of resistant | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| G4T10 | NZ | XC | SH | YC | YC | YC | SY | HX | HX | ||
| 130701 | 130710 | 130723 | 130820 | 130828 | 131115 | 091027 | 130709 | 130709a | |||
| PC-G | 40/S | 42/S | 42/S | 40/S | 38/S | 39/S | 42/S | 38/S | 40/S | 54/S | |
| AMO | 40/S | 39/S | 42/S | 40/S | 39/S | 40/S | 42/S | 40/S | 43/S | 55/S | |
| AMP | 36/S | 38/S | 36/S | 34/S | 38/S | 36/S | 40/S | 34/S | 36/S | 46/S | |
| CEZ | 32/S | 35/S | 35/S | 34/S | 34/S | 32/S | 36/S | 33/S | 34/S | 41/S | |
| CTX | 37/S | 36/S | 36/S | 42/S | 34/S | 34/S | 38/S | 33/S | 37/S | 47/S | |
| SM | 17/S | 12/I | 6.5/R | 6.5/R | 14/I | 14/I | 6.5/R | 12/I | 6.5/R | 23/S | 4 (40) |
| KM | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 10 (100) |
| TC | 26/S | 30/S | 9/R | 10/R | 27/S | 27/S | 12/R | 26/S | 14/R | 39/S | 4 (40) |
| DOXY | 25/I | 30/S | 11/R | 14/R | 25/I | 26/I | 18/R | 27/I | 15/R | 36/S | 4 (40) |
| EM | 32/S | 35/S | 33/S | 34/S | 24/S | 32/S | 30/S | 35/S | 39/S | 44/S | |
| ROXM | 30/S | 31/S | 31/S | 30/S | 22/I | 30/S | 29/S | 27/S | 30/S | 42/S | |
| LCM | 36/S | 33S | 11.5/R | 14/R | 6.5/R | 32/S | 9/R | 30/S | 13/R | 42/S | 5 (50) |
| SXZ | 6.5/R | 6.5/R | 10/R | 8/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 6.5/R | 10/R | 10 (100) |
| ERFX | 36/S | 6.5/R | 16/I | 11/R | 17/I | 19/I | 12/R | 34/S | 15/I | 10/R | 4 (40) |
| CIP | 30/S | 6.5/R | 20/I | 18/I | 18.5/I | 18.5/I | 17/I | 36/S | 18/I | 16/I | 1 (10) |
a) penicillin (PC-G), amoxicillin (AMO), ampicillin (AMP), cefazolin (CEZ), cefotaxime (CTX), streptomycin (SM), kanamycin (KM), tetracycline (TC), doxycycline (DOXY), erythromycin (EM), roxithromycin (ROXM), lincomycin (LCM), sulfisoxazole (SXZ), enrofloxacin (ERFX) and ciprofloxacin (CIP). b) The diameter of antibiotic susceptibility discs is 6.35 ± 0.50 mm. S=susceptible; I=intermediate; R=resistance.